Regeneron Reevaluates Bispecific Antibody Strategy Following Fatalities
TL;DR Summary
Regeneron is reassessing its PSMA/CD28 bispecific antibody development in prostate cancer after two patient deaths occurred during a combination trial with Libtayo. The company has halted patient enrollment in the trial due to the emerging safety profile, including the deaths.
Topics:business#bispecific-antibody#healthcare#immunotherapy#patient-deaths#prostate-cancer#regeneron
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
0 min
vs 1 min read
Condensed
66%
119 → 40 words
Want the full story? Read the original article
Read on Endpoints News